You are here: Industry Insights > MS

News List

Novartis’ MS therapy Kesimpta wins NICE backing pharmatimes
April 22, 2021
Novartis’ Kesimpta has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of relapsing remitting multiple sclerosis (RRMS) in adult patients.
New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis americanpharmaceuticalreview
April 21, 2021
Genentech, a member of the Roche Group, announced new Ocrevus® (ocrelizumab) analyses supporting its significant benefit on disease progression in early-stage relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS) as well as ...
TG Therapeutics’ ublituximab tops Sanofi’s Aubagio in MS trial pharmatimes
April 20, 2021
New York-headquartered biopharma company TG Therapeutics has revealed new data for its investigational therapy ublituximab, which demonstrated superiority over Sanofi’s Aubagio in patients with relapsing forms of multiple sclerosis (MS).
Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS americanpharmaceuticalreview
April 19, 2021
Merck, a leading science and technology company, will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology (AAN) Annual Meeting showing that the investigational Bruton’s tyrosine kinase (BTK) ...
EU nod for new formulation of Biogen's Tysabri pharmatimes
April 13, 2021
European regulators have approved Biogen's application to market a subcutaneous (SC) injection of Tysabri (natalizumab) to treat relapsing-remitting multiple sclerosis (MS).
BrainStorm Announces Positive Topline Data in NurOwn Study for Progressive MS americanpharmaceuticalreview
March 30, 2021
BrainStorm Cell Therapeutics announced topline data from the Company's Phase 2 trial evaluating three repeated administrations of NurOwn® (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS).
US FDA approves Janssen’s PONVORY for relapsing multiple sclerosis pharmaceutical-technology
March 23, 2021
The US Food and Drug Administration (FDA) has approved the Janssen Pharmaceutical Companies of Johnson & Johnson’s (JNJ) PONVORY (ponesimod) for treating adults with relapsing forms of multiple sclerosis (MS).
Once daily multiple sclerosis treatment approved for use in Scotland europeanpharmaceuticalreview
February 10, 2021
The Scottish Medicines Consortium has approved Zeposia® (ozanimod) for use in relapsing remitting multiple sclerosis patients.
EU authorises intramuscular administration of Biogen’s Plegridy for MS pharmatimes
January 07, 2021
A new intramuscular (IM) injection option of Biogen’s Plegridy (peginterferon beta-1a) has been approved by the European Commission for the treatment of relapsing-remitting multiple sclerosis (MS).
Amarna Therapeutics Collaborates with Spanish FPS contractpharma
September 27, 2020
Will examine the efficacy of its SV40-based SVec gene delivery vector in diabetes mellitus type 1 and multiple sclerosis.

Previous page 1 2 3 4 5 6 7 8 9 Next page